NCT04021277View on ClinicalTrials.gov

PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

August 27, 2024

Study Completion Date

September 24, 2024

Conditions
Solid TumorColorectal Cancer
Interventions
DRUG

20 uL/kg PS101

20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks

DRUG

40 uL/kg PS101

40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks

DEVICE

Ultrasound

Ultrasound activation and enhancement

Trial Locations (4)

Unknown

Oslo University Hospital HF, Oslo

CB20QQ

Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge

NE7 7DN

Freeman Hospital, Newcastle upon Tyne

SM25PT

Royal Marsden NHS Foundation Trust, Sutton

Sponsors
All Listed Sponsors
lead

EXACT Therapeutics AS

INDUSTRY

NCT04021277 - PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin | Biotech Hunter | Biotech Hunter